vernakalant (Pending FDA Approval)

Brand and Other Names:Brinavess

Dosing & Uses

Atrial Fibrillation

IV antiarrhythmic pending FDA approval for rapid conversion of recent onset atrial fibrillation to sinus rhythm

Next:

Pharmacology

Mechanism of Action

Acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion

Prominently blocks certain potassium channels, specifically, the atrial-selective potassium current Iκur

It is also a sodium channel blocker, depending upon heart rate (HR); as HR increases, affinity for the sodium channel increases; additionally, as the HR decreases, vernakalant binding to the sodium channel decreases

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.